首页> 美国卫生研究院文献>Annals of Oncology >P-288Global Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Compare Efficacy and Safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Plus nab-Paclitaxel and Gemcitabine vs. Placebo Plus nab-Paclitaxel and Gemcitabine

【2h】

P-288Global Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Compare Efficacy and Safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Plus nab-Paclitaxel and Gemcitabine vs. Placebo Plus nab-Paclitaxel and Gemcitabine

机译：P-288全球3期随机双盲安慰剂对照的多中心研究比较PEG化重组人透明质酸酶（PEGPH20）加nab-紫杉醇和吉西他滨与安慰剂加nab-紫杉醇和吉西他滨的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Annals of Oncology
作者
Tempero Margaret; Hingorani Sunil; Zheng Lei; Reni Michele; Hendifar Andrew; Ducreux Michel; Bullock Andrea; Corrie Pippa; Harris William; Heinemann Volker; Seery Tara; Wu Wilson; Chondros Dimitrios; Van Cutsem Eric;
展开▼
作者单位

展开▼
年(卷),期 -1(27),Suppl 2
年度 -1
页码 ii84
总页数 1
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第1期

机译：随机，双盲，安慰剂对照期II研究ISTIATUMAB（MM-141）加上Nab-PACLITAXEL和GEMCITABINE与NAB-PACLITAXEL和吉西他滨，在前线转移性胰腺癌（CARRIE）
2. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. [J] . Gao R, Zhang J, Cheng L, Journal of the American College of Cardiology . 2010,第18期

机译：基于标准疗法的安慰剂对照研究，II期随机，双盲，多中心研究，研究了重组人神经调节蛋白-1在慢性心力衰竭患者中的疗效和安全性。
3. Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial [J] . Wang Guogan, Wang Pengbo, Li Yishi, Medicine. . 2016,第9期

机译：急性失代偿性心力衰竭患者1小时输注重组人心房利钠肽的疗效和安全性III期，随机，双盲，安慰剂对照的多中心试验
4. PD-006Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients utilizing Ventana companion diagnostic assay [O] . S. Hingorani, A. Bullock, W. Harris, -1

机译：PD-006使用Ventana伴随诊断测定法对先前未经治疗的IV期胰腺癌患者进行PEGPH20加nab-紫杉醇/吉西他滨的随机2期研究的1期数据的最终分析
5. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) [O] . M. Kundranda, A.C. Gracian, S.F. Zafar, 2020

机译：Istatumab（mm-141）的随机，双盲，安慰剂对照期II研究加上Nab-Paclitaxel和Gemcitabine与Nab-Paclitaxel和吉西他滨在前线转移性胰腺癌（Carrie）

P-288Global Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Compare Efficacy and Safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Plus nab-Paclitaxel and Gemcitabine vs. Placebo Plus nab-Paclitaxel and Gemcitabine

著录项

相似文献

相关主题

期刊订阅